التفاصيل البيبلوغرافية
| العنوان: |
Contrasting clinical characteristics and treatment patterns in women with newly diagnosed advanced-stage epithelial ovarian cancer in Australia, South Korea and Taiwan. |
| المؤلفون: |
Hung-Hsueh Chou, Fereday, Sian, DeFazio, Anna, Chih-Long Chang, Bowtell, David, Heng-Cheng Hsu, Traficante, Nadia, Soo Young Jeong, Wen-Fang Cheng, Ariyarantne, Dinuka, Teresa Tung, Rajadhyaksha, Viraj, Won-Hee Lee, Brown, David, Byoung-Gie Kim |
| المصدر: |
Journal of Gynecologic Oncology; Jan2023, Vol. 34 Issue 1, p1-19, 19p |
| مصطلحات موضوعية: |
OVARIAN epithelial cancer, OVARIAN cancer, CYTOREDUCTIVE surgery, DIAGNOSIS, PROGRESSION-free survival, BEVACIZUMAB |
| مصطلحات جغرافية: |
TAIWAN, SOUTH Korea, AUSTRALIA |
| مستخلص: |
Objective: The real-world INFORM study analyzed sociodemographics, treatment patterns and clinical outcomes for patients with newly diagnosed advanced epithelial ovarian cancer (EOC) in Australia, South Korea (S.Korea) and Taiwan preceding incorporation of poly(ADPribose) polymerase inhibitors into clinical practice. Methods: Retrospective data from patients diagnosed with EOC (high-grade serous EOC for Taiwan) between January 2014 and December 2018 with =12 months follow-up from diagnosis were analyzed descriptively. Survival was evaluated by Kaplan-Meier with two-sided 95% confidence interval (CI). Results: Of the 987 patients (Australia, 223; S.Korea, 513; Taiwan, 251), 98% received platinum-based chemotherapy (CT). In S.Korea and Taiwan 76.0% and 78.9% respectively underwent primary cytoreductive surgery; in Australia, 56.5% had interval debulking surgery. Bevacizumab was included in primary/maintenance therapy for 22.4%, 14.6% and 6.8% of patients in Australia, S.Korea and Taiwan, respectively. Patients receiving bevacizumab were high-risk (reimbursement policy) and achieved similar real-world progression-free survival (PFS) compared with CT only. Overall, the median real-world PFS (months; 95% CI) was similar across Australia (16.0 [14.63-18.08]), S.Korea (17.7 [16.18-19.27]) and Taiwan (19.1 [17.56-22.29]). Conclusion: This study reveals poor prognosis despite differences in demographics and treatment patterns for patients with EOC across Asia-Pacific suggesting the need for biomarker-driven novel therapies to improve outcomes. [ABSTRACT FROM AUTHOR] |
|
Copyright of Journal of Gynecologic Oncology is the property of Korean Society of Gynecologic Oncology & Colposcopy and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder